PerkinElmer uses cookies to ensure that we give you the best experience possible on our website. This may include cookies from third party websites. If you continue without changing your settings, we will assume that you consent to receive cookies from this website. You can change your cookie settings at any time. To learn more, please review our cookie policy, which includes information on how to manage your cookies.
Press Conference

Recent Media Coverage

Read recent articles about PerkinElmer below. Clicking a headline will take you to the publication’s website for the full article.

PerkinElmer Focusing on Life Sciences, Diagnostics as it Divests Other Businesses

PerkinElmer leaders anticipate faster growth and investment in both the Company’s pure-play Life Sciences and Diagnostics business, as well as the Applied, Food and Enterprise Services businesses it has announced its intention to divest. Additional commentary and analysis on the forthcoming transaction is available in this 360Dx article.

A Global Surveillance Model is Vital for Future Pandemic Prevention

Broad viral surveillance is essential in pandemic prevention to allow for the detection of potential threats and the early launch of health protocols against pathogens. The enduring challenge is the current lack of a universal program or tool to allow for the real-time viral monitoring needed to prevent outbreaks entirely. Yves Dubaquie, senior vice president of diagnostics, PerkinElmer, Inc., unveils a comprehensive model with a three-level approach.

Tackling drug resistance in immuno-oncology: the role of combinational therapy

The application of immunotherapy for cancer treatment has burgeoned during the past decade, transforming the way certain types of cancer are managed. However, many patients do not respond to immunotherapy or they develop resistance to the treatment. Amanda Jones, life science research strategy leader at PerkinElmer, shares insights on the topic, explains current challenges and highlights the promise of personalized therapy.

A Moment in the Sun

Founder and Outgoing CEO of Oxford Immunotec, a PerkinElmer company, Peter Wrighton-Smith shares his perspective on the recent recognition of the importance of T cells, explaining their crucial role in the immune system and how they may help fight future pandemics.

PerkinElmer and Novartis announce collaboration to combat sickle cell disease in Africa

PerkinElmer is collaborating with Novartis to improve sickle cell disease (SCD) screening and treatment across sub-Saharan Africa. The program aims to expand advocacy efforts to educate patients, caregivers and communities about the importance of newborn screening and early intervention with hydroxyurea (HU) and other SCD treatments.

Preeclampsia testing: tackling pregnancy dangers

In this article, Telle Ukonaho, global business development manager of reproductive health at PerkinElmer, outlines the ways pre-eclampsia testing can help save lives, the dangers of the condition and the demographics that are at most risk. PerkinElmer has innovated and collaborated with global experts, scientific and medical communities since 2004 to identify new biomarkers for the prediction of adverse outcomes of pregnancy, including those to predict pre-term pre-eclampsia.

Proteogenomics: When Genomics Is Not Enough

In this article on the power of combining RNA, DNA and protein insights for improved cancer research, Dipesh Risal, senior product marketing manager of proteogenomics at BioLegend explains how the TotalSeq workflow adds proteomics to single-cell RNAseq experiments.

Identifying, Tracking, and Mitigating Future Outbreaks

Arvind Kothandaraman, managing director of specialty diagnostics at PerkinElmer, discusses how to build a global surveillance model for pandemic preparedness through a three-pronged approach in this thought leadership blog.

Methods for Single-Cell Isolation

Arvind Kothandaraman, managing director for specialty diagnostics at PerkinElmer, explains the value of new single-cell technologies, including the HIVE™ scRNAseq Solution from Honeycomb Biotechnologies, that can help provide personalized treatment and drive better health outcomes.

5 Lab Strategies to Strengthen Pandemic Prevention and Preparedness Efforts

From comprehensive disease surveillance to better hiring and retention practices, our Managing Director of Specialty Diagnostics Arvind Kothandaraman outlines strategies clinical labs will use to meet the challenges of future viral outbreaks in this contributed article.

Evolution of Lyme Disease Testing and Future Perspectives

Lyme disease has been a nationally recognized condition in the United States since 1991 and is the most common vector-borne illness in North America and Europe. Scientific Affairs Manager Maite Sabalza and Scientific Affairs Associate Ilana Heckler at EUROIMMUN, a PerkinElmer company, demystify Lyme disease’s transmission and diagnosis while sharing future perspectives.

5 Trends Impacting the Dairy Industry

In this article, PerkinElmer’s R&D Manager specializing in food and dairy, Wopke Beukema, identifies five trends changing the dairy industry as well as some ways that processors can capitalize on them to “add new firepower to their value and quality.”

Developing Therapeutics for Huntington’s Disease: Challenges, Opportunities and the Future

In the second part of this two-part series, Dr. Christian Landles, senior research associate in neurodegenerative diseases at UCL Queen Square Institute of Neurology, discusses the development of therapies for rare diseases such as HD and how technologies such as those offered by PerkinElmer can help develop a more targeted biomarker and drug discovery approach to counter mutant huntingtin protein to improve treatment options for people with HD.

Driving Forward Huntington’s Disease Research

In the first part of this interview series, Dr. Christian Landles, senior research associate in neurodegenerative diseases at UCL Queen Square Institute of Neurology, highlights recent progress in understanding Huntington’s Disease (HD) as well as the importance of HD biomarker characterization and identification. PerkinElmer is proud to be supporting Dr. Landles’ research with its custom labelling service utilizing PerkinElmer’s AlphaLISA and HTRF technologies, microplates, and EnVision plate reader, generously supported by grants from the CHDI Foundation and UK Dementia Research.

Baby’s first genome

Projects underway in the United States and UK are evaluating the use of whole-genome sequencing (WGS) as a screening tool for healthy newborns. In this article, Madhuri Hegde, SVP and chief scientific officer of global laboratory services at PerkinElmer, describes the value of WGS as a lifelong medical reference for families and provides details on PerkinElmer’s cord blood banking business, ViaCord.

The State of Play of Microplastics

In this article, PerkinElmer’s EMEAI regional segment leader environmental, Luca Piatti, shares deep insights about microplastics, some recent research projects on water pollution enabled by PerkinElmer’s technologies, and what the future goals of microplastics research are.

The Therapeutic Potential of iPSCs in Personalized Medicine

Human induced pluripotent stem cells (iPSCs) are uniquely positioned to revolutionize the fields of gene therapy and regenerative medicine. In this article written by Amanda Haupt, senior scientist and R&D project manager at Horizon Discovery, a PerkinElmer Company, she shares with us the importance of maintaining a reliable and consistent iPSC culture and the benefits of gene editing technologies for progressing therapeutic iPSCs.

Molecular genetic testing for autoimmune diseases

In this article coauthored by PerkinElmer’s Madhuri Hegde, Ilana Heckler and Azadeh Bojmehrani, the three experts illustrate how genetic parameters are now an integral part of routine autoimmune diagnostics.

Stemming the Spread of Dengue through Vaccination

EUROIMMUN Scientific Affairs Manager Maite Sabalza discusses the importance of pre-vaccination screening for dengue vaccines and the role that local laboratories in Puerto Rico are playing in helping more children and adolescents gain access to them.

PerkinElmer teams with CRG for diabetes gene therapy

SIRION Biotech, a PerkinElmer Company, has partnered with the Center for Genomic Regulation (CRG) in Barcelona, Spain to develop adeno-associated virus (AAV) vectors for type 1 and 2 diabetes.

Driving Change in Rare Disease Diagnostics

In the first part of a two-part rare disease interview, Madhuri Hegde, senior vice president and chief scientific officer, discusses the hurdles in rare disease diagnostics and how recent advances in genomic and molecular testing have improved the diagnostic process.

PerkinElmer highlights new workflows at SLAS 2022

In this interview with PerkinElmer’s Strategy Leader for Biotherapeutics Drug Discovery Glen Molotnikov and General Manager of Applied Genomics James Atwood, the two experts shed lights on the Company’s JANUS G3 Assay Development workstation as well as the HIVE scRNAseq Solution for single-cell isolation and analysis.

SLAS 2022: Life science firms meet pandemic's challenges

In this conversation at the meeting of the Society for Laboratory Automation and Screening (SLAS), Alan Fletcher, senior vice president of life sciences at PerkinElmer, introduces how the Company has been transforming its portfolio in the past year through a number of acquisitions.

Whole genome sequencing for newborn screening

Sukhvinder Nicklen, PerkinElmer market development leader, outlines the potential of whole genome sequencing for newborn screening to detect a wide range of genetic disorders.

WGS in the UK

The UK government has pledged £5 billion towards health-related R&D, including a pilot programme for genome sequencing in newborns. Chris Hughes, managing director of PerkinElmer UK & Ireland, discuses how whole genome sequencing can benefit future generations.

2022: The Year We Implement COVID-19 Lessons Into Practice

The COVID-19 pandemic has taught us the importance of jointly developing diagnostics tools and technologies for the betterment of the entire world. Three PerkinElmer thought leaders share their perspectives on what are expected in 2022, including increasing collaboration, focusing on T cell response and advancing antibody measurement.

How Multiomics Will Continue Improving Healthcare Outcomes in 2022

In 2022, Dr. Madhuri Hegde predicts that there will be increased interest and applications of multiomics in healthcare. In a recent article for Labcompare, Dr. Hegde, our SVP and Chief Scientific Officer for Global Lab Services, explains further how multiomics will continue to improve our understanding of the human genome and with broad applications, benefit global public health for years to come.

Compounders face testing times

In this article, Gerlinde Wita, global market manager, materials, energy & petrochem at PerkinElmer, discusses the problems that the polymer analysis industry is looking to address and the solutions to them.

Navigating Flu Season during the COVID-19 Pandemic

Arvind Kothandaraman, managing director, specialty diagnostics at PerkinElmer, uncovers the design of multianalyte tests that help conserve precious resources and differentiate COVID-19, flu and respiratory syncytial virus.

Clinical Laboratories: 15 Industry Predictions for 2022

Arvind Kothandaraman, managing director of specialty diagnostics, and Ishu Venkataraman, associate director of scientific affairs for EUROIMMUN US, shared their thoughts around the impact of antibody technologies and collaboration on the diagnostics landscape as we’re entering 2022.

Keeping grains glorious

Wheat testing solutions need to be accurate and efficient throughout the supply chain. PerkinElmer's Global Market and Portfolio Manager Wes Shadow explains how innovative testing tools and approaches can be beneficial for food processors.

Ushering in open science: Will COVID-19 forever change research and development?

The COVID-19 pandemic has brought significant changes to the R&D landscape in the past two years. PerkinElmer Managing Director of Specialty Diagnostics Arvind Kothandaraman shared his perspective on increasing collaborations, including shared online data supported by Next Generation Sequencing.

Controls and reagents as the ‘X-Factor’ in modern labs

Discussions of laboratory innovations are oftentimes focused on automation and the other advanced technologies that optimize and accelerate the work of scientists. Controls and reagents, however, play an equally important role – if not more so – in the modern clinical lab.

Saliva Test Developed in NYC Makes COVID Tests Less Invasive

Mount Sinai Health System is making COVID-19 testing less invasive and more efficient for local schools, businesses and other organizations. FOX 5 recently took a look inside the lab, which also features several PerkinElmer instruments.

Improved Sensitivity and Multiplexing in COVID-19 Diagnostic Assays

Arvind Kothandaraman, managing director of specialty diagnostics at PerkinElmer, shares the concept and benefits of pooling tests while describing PerkinElmer’s PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel Assay, and his take on the outlook of COVID-19 diagnostics.

New Tool to Help Speed Up Life-Saving Drug Treatments

PerkinElmer’s automated explorer™ G3 workstation and Opera Phenix HCS technologies will help the University of Colorado’s Anschutz Medical Campus exponentially speed up its drug discovery work around diseases such as cancer, diabetes, cardiovascular disease and Alzheimer’s.

EUROIMMUN qualitative and semi-quantitative IgG test receives FDA EUA

Based on EUROIMMUN’s Anti-SARS-CoV-2 QuantiVac ELISA (IgG) that received CE mark in November 2020, the Anti-SARS-CoV-2 S1 Curve ELISA (IgG) has obtained EUA from the FDA. This assay allows for the qualitative and semi-quantitative detection of IgG antibodies formed against the SARS-CoV-2 S1 antigen.

PerkinElmer Receives FDA Emergency Use Authorization for Respiratory COVID-19 Panel

The FDA has granted EUA for PerkinElmer’s PKamp Respiratory SARS-CoV-2 RT-PCR Panel 1 assay, which simultaneously detects and differentiates SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus (RSV). This will alleviate confusion from similar symptoms amid a possible "twindemic" of COVID-19 and influenza.

40th Anniversary Recollections & Predictions

In this special issue of GEN, the magazine uncovers major milestones and predictions from thought leaders in biotechnology and life sciences. PerkinElmer’s Senior Vice President of Life Science Alan Fletcher and Associate Director of Scientific Affairs at EUROIMMUN, a PerkinElmer company, Iswariya Venkataraman, share their insights around personalized medicine and automated immunofluorescence microscopy.

Determining Shelf Life: Reading the Stability Testing Data

Stability testing is able to ensure the safety and efficacy of a drug product’s shelf life. Anis H. Khimani, senior strategy leader of pharma development at PerkinElmer Life Sciences, shares insights around the importance of stability tests for small-molecule drugs and how they differ from tests of biologics.

Breaking Away from DNA Breaks

Andrea Frapporti from Horizon Discovery, a PerkinElmer company, introduces the applications of base and prime editing in cell and gene therapy, including their differences, limitations and future developments.

Optimizing the Utilization of Lab Assets

Optimizing the usage of equipment and instruments is crucial for lab managers. PerkinElmer’s Carola Schmidt, global director of automated solutions, and Jim Sweeney, senior product manager, global services shared their thoughts on the management of lab assets as well as the metrics and measurement of lab efficiency.

ctDNA and Cancer: Diagnostics, Treatments, and Monitoring

Amar Kamath, VP and general manager of Diagnostics at PerkinElmer, and Aldo Mele, senior scientist 2 at Horizon Discovery, a PerkinElmer company, share insights on how circulating tumor DNA (ctDNA) can be a promising method of routine testing for cancer care.

Screening Saves Lives, So Why don’t Governments Fund it?

Funded by the American Society of Hematology, the Consortium on Newborn Screening in Africa (CONSA) aims to screen 10,000–16,000 babies per year over the next 5 years across Africa for sickle-cell disease. PerkinElmer is supporting the effort with donations and local training.

Top Women in Precision Medicine

Madhuri Hegde, senior vice president and chief scientific officer at PerkinElmer Genomics, is featured in Clinical OMICs’ annual selection of women making their mark in precision medicine. Dr. Hegde shares her life stories and experiences that have led to her success in the field.

Powering Diagnostics for Infectious Disease

According to industry experts, COVID-19 may have accelerated interest in next-generation sequencing (NGS). PerkinElmer Genomics SVP and Chief Scientific Officer Madhuri Hegde comments on advances in NGS technologies and its potential applications in infectious disease diagnostics.

BioLegend to Be Acquired for $5.25 Billion

PerkinElmer has agreed to acquire BioLegend, a global leader of antibodies and reagents. This will be the largest transaction in PerkinElmer’s history and expand PerkinElmer’s and extend their life science franchise into new segments.

What to Know About the Coronavirus Lambda Variant

As a “variant of interest” labeled by the WHO, the lambda variant has been circulating in multiple countries. Iswariya Venkataraman, PhD, associate director of scientific affairs at EUROIMMUN, a PerkinElmer company, talks about how new variants arise in communities.

Don’t Break My Strands

For cancer immunotherapy, multiple gene knockouts are required to augment the properties of the immune cell used for treatment. Emily M. Anderson, a principal scientist from Horizon Discovery, a PerkinElmer company, introduces how the DNA double-strand breaks (DSBs) could have an impact.

PerkinElmer’s Support Creates World’s Largest Public Cell Painting Dataset

PerkinElmer is providing its PhenoVue Cell Painting Kits to the Joint Undertaking in Morphological Profiling-Cell Painting (JUMP-CP) consortium, which is led by the Broad Institute of MIT and Harvard and focused on creating and sharing the world’s largest, public cell imaging data set.

NIH Study Offers Evidence of Early SARS-CoV-2 Infections in the U.S.

PerkinElmer’s EUROIMMUN SARS-CoV-2 ELISA (IgG) is one of two antibody tests used by the NIH’s All of Us program, which recently published evidence of SARS-CoV-2 infections in five U.S. states earlier than had initially been reported.

PerkinElmer CEO Prahlad Singh Talks Business Transformation on CNBC’s Mad Money

Our President and CEO Prahlad Singh recently joined Jim Cramer on CNBC’s Mad Money to describe how agility and innovation continue to fuel PerkinElmer's transformation. In this interview, Prahlad talked about the Company's recent acquisitions and future opportunities in the Life Sciences and Diagnostics sectors.

Getting Ahead of the Mycotoxin Testing Curve

Mycotoxins pose many challenges for feed and grain suppliers at every stage from harvest to final production. Mark MacBeath, Food Safety Product leader, and Wes Shadow, Global Market manager of Grain, outline the best technologies to aid mycotoxin monitoring and detection.

Can Immune Cell-Based Therapies Become Mainstream in Oncology?

Can gene editing technology help transition cell-based therapies to solid tumors? Jonathan Frampton, a Corporate Development Partner on our Horizon Discovery team, looks at the potential evolution of this currently costly approach into mainstream treatment of cancer patients through the application of base editing.

The Importance of E. coli Detection Methods

E. coli O157 testing has gained more attention from food producers and processors as the demand grows rapidly. Nevin Perera, Research and Development Manager at PerkinElmer, shares his insights about the steps to take to ensure safe and efficient E. coli testing.

How to Orchestrate Your Drug Discovery Journey

Standardization and validation are foundations in the selection of appropriate technology, methods, reagents and consumables. Anis H Khimani, Senior Strategy and Market Segment Leader at PerkinElmer Life Sciences, discusses how to orchestrate these factors towards a holistic outcome.

Viral Evolution Insights Will Help Us Fight COVID-19

One takeaway from COVID-19 is that understanding the mechanisms of viral evolution can help track variants in real time. Arvind Kothandaraman, our general manager of specialty diagnostics, explains how new and emerging technologies have enabled scientists and research to identify and monitor SARS-CoV-2 mutations.

Evolving Analytical Technology Unravels Protein Characteristics

Anis H. Khimani, senior strategy and product portfolio leader for Life Sciences at PerkinElmer, talks about the innovations and challenges in advancing capabilities for protein analytics to ensure the rapid development of safe and effective biotherapeutics.

Lab Automation in a Post-COVID World: 5 Questions to Ask and Answer

Automation has helped many labs keep pace with new and increasing demands brought on by COVID-19. In this article, our Global Director of Automated Solutions Carola Schmidt shares advice on how to setup new technology initiatives for success.

Next-Generation Sequencing for SARS-CoV-2 Surveillance

Next-generation sequencing (NGS) plays a vital role in COVID-19 surveillance. Our General Manager of NGS Michelle Fraser shares her thoughts on the latest advances in NGS technology and the global effort to track the virus and its variants.

Best Practices in HPLC to UHPLC Method Transfer

As the demand for faster separations, better peak resolution and lower detection limits increases, more food, pharma and industrial labs are moving from high performance liquid chromatography (HPLC) to ultra-high-performance liquid chromatography (UHPLC). Jackie Trudell, Portfolio Marketing Manager Chromatography and Mass Spectrometry, discusses the benefits and key considerations in making the transition smoothly.

Cell Painting: A Vibrant Future for Phenotypic Drug Discovery

Cell painting allows new strategies for high-content screening (HCS) practitioners to identify new drug candidates and study mechanisms of action by taking advantage of both cellular imaging and machine learning. Alexander Schreiner, high content screening applications leader, and Martin Daffertshofer, high content screening software product manager from PerkinElmer, discuss how cell painting is helping drug discovery and the current technical limitations and challenges.

Base Editing: The Next Frontier in Genome Editing Technology

Jonathan Frampton, a Corporate Development Partner on our Horizon Discovery team talks about how base editing differs from traditional genome editing tools and the exciting advances it could help help bring about, especially in cell-based therapy discovery.

Automation Extends Its Reach in Drug Discovery

Lab automation is increasingly critical for typical discovery and basic life science workflows. PerkinElmer’s executive director for science and technology David Gosalvez walks us through the key challenge for labs to adapt to modern, efficient systems that maximize the potential of instruments, time, and people.

The Evolving Problem of Microplastics in a PPE Era

In part one of a two part microplastics series, Kathleen A. Young, Environmental Market Leader at PerkinElmer, shares her thoughts on how PPE has increasingly impacted our environment and the importance of standardization in detecting microplastics.

PerkinElmer, Insightful Science to Integrate Software with Cloud-Based Data

PerkinElmer announced its Signals informatics platform will integrate with software from Insightful Science to expand on existing capabilities in the biologics drug discovery space, which will reduce research cycle times and accelerate biologics and vaccine development.

The Future of COVID Testing

Prahlad Singh, President and CEO of PerkinElmer, sat down with This Week in Business on NECN to talk about the Company’s COVID-19 RT-PCR and antigen tests, and how he perceives the COVID-19 testing landscape to be as vaccines roll out.

Celebrating Women Empowerment

To commemorate International Women’s Day, Nicky Xu, General Manager of Diagnostics at PerkinElmer Greater China, shared how she led the development of the COVID-19 PCR test and organized national donations as a female leader.

Waltham Company Seeking FDA Approval for Rapid Test

Masoud Toloue, Senior Vice President of PerkinElmer Diagnostics, talked with 7News in Boston about PerkinElmer’s antigen test that detects SARS-CoV-2 nucleocapsid antigen in under 15 minutes. The test is expected to play an important role in point-of-care testing located at healthcare centers, travel hubs, businesses and schools.

Now on Base, Rutgers Team Reveals New Genome Editing Approach

Horizon Discovery, a PerkinElmer company, was licensed by Rutgers University for the modular base editing system that uses RNA aptamers to position DNA modifying enzymes at genome targets. This uses a pin-point system and can enhance the therapeutic potential of genome editing.

Choosing Reference Standards for Molecular Assay Development

Next-generation sequencing (NGS) is used to detect underlying molecular mechanisms and variants in multiple genes to achieve targeted treatment for cancer patients. Keith Cannon, Director of Commercial Product Management and Prabha Nagarajan, Senior Research Scientist at Horizon, a PerkinElmer company, highlight the importance and prospect of NGS initiatives.

PerkinElmer Launches its First Cell Painting Kit

As an addition to the PhenoVue cellular imaging reagent portfolio, PerkinElmer’s first cell painting kit completes the suite of high-content screening products and expert services to build more streamlined workflows.

The Impact of Emerging SARS-CoV-2 Variants on Diagnostic Testing

Arvind Kothandaraman, PerkinElmer’s General Manager, Specialty Diagnostics, discusses how the emerging genetic variants of SARS-Cov-2 can impact false negative rates and the characteristics RT-PCR assays need to remain accurate.

Proteomics Begins to Emerge from Genomics’ Shadow

John Rontree, Portfolio Director and Leader of Mass Spectrometry and Anis H. Khimani, senior strategy and market life sciences segment leader in life sciences at PerkinElmer share their thoughts on quantitation, automation and innovative assays in proteomics as an approach to understanding their role in complex biological systems, supporting high-throughput PCR testing environments and helping drive innovative therapeutics development for COVID-19.

Neutralizing Antibodies in the Fight against COVID-19

Since their discovery last year, coronavirus neutralizing antibodies have been touted as possible treatments and diagnostic targets. Anis H. Khimani, Senior Strategy and Market Segment Leader at PerkinElmer and Kai Fechner, Director of International Sales and Marketing at EUROIMMUN (a PerkinElmer company), talk about what defines an ideal NAb assay.

PerkinElmer E. coli Pathogen Detection for Beef & Beef Trim Testing

While most Escherichia coli strains are harmless, some can cause intestinal illness in groups under higher risk. PerkinElmer’s newly launched Solus One O157 Pathogen Detection Assay provides a highly sensitive, cost effective system with an industry-leading result sample volume.

Pandemic Pivot: How Scientists Answered the Call for Diagnostic Tests

As one of the world’s largest suppliers of laboratory and diagnostic reagents and equipment, PerkinElmer was in prime position to respond to COVID-19. As the pandemic took hold, Iswariya Venkataraman, scientific affairs manager at EUROIMMUN US, a PerkinElmer subsidiary, shares how the Company developed its now-established qualitative test to assist vaccine developers in understanding if their products elicited antibody responses, and how strong those responses were.

Vaccine innovation in the Age of COVID-19 & Beyond

Dr. Sanjay Garg, Operations of Sanofi Pasteur and our own Dr. Anis H. Khimani discuss how the COVID-19-driven innovation and collaboration cycles are changing vaccine development forever.

PerkinElmer to Acquire Oxford Immunotec for $591M

Through the acquisition of Oxford Immunotec, a leading company specialized in diagnosing infection with tuberculosis, PerkinElmer will grow its portfolio of advanced infectious disease testing solutions to include tuberculosis detection to better serve customers around the world.

Trendspotting: What’s Coming For Bio-IT In 2021

Arvind Kothandaraman, PerkinElmer’s General Manager, Specialty Diagnostics, talks about trends and predictions including additional forecasts for cross-biotech collaboration and the significance of digital technologies.